DoW Amyotrophic Lateral Sclerosis Research Program, Pilot Clinical Trial Award
Grant Opportunity Analysis
The Defense Health Agency’s FY26 Amyotrophic Lateral Sclerosis Research Program Pilot Clinical Trial Award, administered by the Department of the Army through USAMRAA, funds clinical trials intended to improve the treatment or management of amyotrophic lateral sclerosis. The award supports rapid implementation of phase 1 to small-scale phase 2 studies in two focus areas: biomarker-driven interventions and clinical care for ALS symptom management. Projects using therapeutic interventions must incorporate intervention-specific biomarkers, and applications must include community collaboration, a detailed regulatory strategy, and a transition plan for moving successful results to the next development stage. Approximately $5.6 million is available for two awards capped at $2.8 million over three years, with a pre-application due June 24, 2026 and a full application due September 30, 2026.